Results 141 to 150 of about 887,943 (333)
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
Nature CommunicationsDespite the development of novel therapies for acute myeloid leukemia, outcomes remain poor for most patients, and therapeutic improvements are an urgent unmet need. Although treatment regimens promoting differentiation have succeeded in the treatment of
Edurne San José-Enériz +29 more
doaj +1 more source
Mesoporous Bioactive Glasses: A Powerful Tool in Tissue Engineering and Drug Delivery
Advanced Healthcare Materials, EarlyView.This work is a comprehensive revision of bioactive glasses (BGs), pioneered by Prof. L.L. Hench, which are key in bone repair and regenerative medicine. Sol–gel methods and mesoporous designs enhanced their bioactivity, ions, and drug delivery. BGs now support gene therapy and 3D‐printed scaffolds, enabling personalized, multifunctional treatments in ...
Natividad Gómez‐Cerezo +3 more
wiley +1 more source
Tumor Biology, 2017 Acute myeloid leukemia is characterized by its high biological and clinical heterogeneity, which represents an important barrier for a precise disease classification and accurate therapy.
Alberto Ponciano-Gómez +5 more
doaj +1 more source
Haematologica, 2010 Background Residual chronic myeloid leukemia disease following imatinib treatment has been attributed to the presence of quiescent leukemic stem cells intrinsically resistant to imatinib.
Fabrizio Vianello +10 more
doaj +1 more source
Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells [PDF]
, 2001 The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We
Aicher, A +9 more
core
Pediatric acute myeloid leukemia/ myeloid sarcoma: A series of cases with rare presentations
Pediatric Hematology Oncology Journal, 2022 Malav Thakkar, Maharshi Trivedi
semanticscholar +1 more source
Advanced Materials, EarlyView.An advanced‐fidelity CRISPR nuclease, FnCas9‐AF2, is rationally engineered to discriminate single‐base mismatches with unprecedented level precision. Integrated into the MUTE‐Seq workflow, FnCas9‐AF2 depletes wild‐type cell‐free DNA, thereby exposing rare tumor‐derived mutant DNA (a molecular “needle in a haystack”).
Sunghyeok Ye +20 more
wiley +1 more source
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling
Haematologica, 2009 We examined the gene expression profiles of two independent cohorts of patients with acute myeloid leukemia [n=247 and n=214 (younger than or equal to 60 years)] to study the applicability of gene expression profiling as a single assay in prediction of ...
Roel G.W. Verhaak +8 more
doaj +1 more source
Advanced Therapeutics, EarlyView.This review covers the mechanical forces experienced by immune cells through cell–cell and cell–extracellular matrix interactions and how these forces influence their receptors and functions. These relationships between forces and cellular functions can be exploited using engineering techniques to modify the physical properties of materials for novel ...
Yu‐Chang Chen +2 more
wiley +1 more source
Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient
Hematology Reports, 2014 Acute myeloid leukemia (AML) is a hematological malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for ...
Harry Ross Powers +4 more
doaj +1 more source